Transpacific TAVR Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorDuk-Woo Park, MD
About this trial
This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients undergoing TAVR
Informed consent
Disqualifiers
None
Trial population
All patients undergoing TAVR
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
TAVR
Procedure/Surgerytranscatheter aortic valve replacement (TAVR)
Treatment groups
10,000 Participants
are divided into 4 treatment groupsGroup A: Korea Centers1 intervention
Group B: Stanford University1 intervention
Group C: Northwestern University1 intervention
Group D: Cheng-Hsin Hospital1 intervention
Trial outcomes
Primary outcomes
1
Event rate of all cause death
Time frame
1 yearSecondary outcomes
1
Event rate of cardiovascular death
A. Death due to proximate cardiac cause B. Death caused by non-coronary vascular condition C. All procedure-related death D. All valve-related death E. Sudden or unwitnessed death F. Death of unknown cause
Time frame
10 years2
Event rate of myocardial infarction
according to Valve Academic Research Consortium (VARC) criteria
Time frame
10 years3
Event rate of cerebrovascular accident
stroke and TIA (Transient Ischemic Attack)
Time frame
10 years4
Event rate of bleeding
according to Valve Academic Research Consortium (VARC) criteria
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Duk-Woo Park, MD
Lead sponsor
Asan Medical Center
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator
Source ClinicalTrials.gov